VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Código da empresaVNRX
Nome da EmpresaVolitionRX Ltd
Data de listagemFeb 06, 2015
CEODr. Jasmine Kway
Número de funcionários85
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 06
Endereço1489 West Warm Springs Road
CidadeHENDERSON
Bolsa de valoresNYSE American Consolidated
PaísUnited States of America
Código postal89014
Telefone17024251561
Sitehttps://volition.com/
Código da empresaVNRX
Data de listagemFeb 06, 2015
CEODr. Jasmine Kway
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados